Switching to DTG/3TC fixed-dose combination (FDC) Is non-inferior to continuing a TAF-based regimen in maintaining virologic suppression through 48 weeks (TANGO Study). Issue 2 (February 2020) - Van Wyk, J.; Ajana, F.; Bisshop, F.; De Wit, S.; Osiyemi, Y.; Portilla, J.; Routy, J.; Wyen, C.; Ait-Khaled, M.; Nascimento, M.; Pappa, K.; Wang, R.; et al.